Protein Engineering and Preclinical Development of a GM-CSF Receptor Antibody for the Treatment of Rheumatoid Arthritis

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2012 Aug 24

PMID 22913645

Citations 13

Authors

R R Minter

E S Cohen

B Wang

M Liang

I Vainshtein

G Rees

L Eghobamien

P Harrison

D A Sims

C Matthews

T Wilkinson

P Monk

C Drinkwater

L Fabri

A Nash

M McCourt

L Jermutus

L Roskos

I K Anderson

M A Sleeman

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: For antibody therapies against receptor targets, in vivo outcomes can be difficult to predict because of target-mediated clearance or antigen 'sink' effects. The purpose of this work was to engineer an antibody to the GM-CSF receptor α (GM-CSFRα) with pharmacological properties optimized for chronic, s.c. treatment of rheumatoid arthritis (RA) patients.

Experimental Approach: We used an in silico model of receptor occupancy to guide the target affinity and a combinatorial phage display approach for affinity maturation. Mechanism of action and internalization assays were performed on the optimized antibody in vitro before refining the modelling predictions of the eventual dosing in man. Finally, in vivo pharmacology studies in cynomolgus monkeys were carried out to inform the predictions and support future clinical development.

Key Results: Antibody potency was improved 8600-fold, and the target affinity was reached. The refined model predicted pharmacodynamic effects at doses as low as 1 mg kg(-1) and a study in cynomolgus monkeys confirmed in vivo efficacy at 1 mg kg(-1) dosing.

Conclusions And Implications: This rational approach to antibody drug discovery enabled the isolation of a potent molecule compatible with chronic, s.c. self-administration by RA patients. We believe this general approach enables the development of optimal biopharmaceuticals.

Citing Articles

Taking phototherapeutics from concept to clinical launch.

Vickerman B, Zywot E, Tarrant T, Lawrence D Nat Rev Chem. 2023; 5(11):816-834.

PMID: 37117665 PMC: 8493544. DOI: 10.1038/s41570-021-00326-w.

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.

Hwang Y, Lu R, Su S, Chiang P, Ko S, Ke F J Biomed Sci. 2022; 29(1):1.

PMID: 34983527 PMC: 8724751. DOI: 10.1186/s12929-021-00784-w.

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody.

Cheng J, Liang M, Carvalho M, Tigue N, Faggioni R, Roskos L Antibodies (Basel). 2020; 9(3).

PMID: 32961882 PMC: 7551206. DOI: 10.3390/antib9030049.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester G, McInnes I, Kremer J, Miranda P, Vencovsky J, Godwood A Arthritis Rheumatol. 2018; 70(5):679-689.

PMID: 29361199 PMC: 5947536. DOI: 10.1002/art.40420.

Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment.

Brennan F, Cavagnaro J, McKeever K, Ryan P, Schutten M, Vahle J MAbs. 2017; 10(1):1-17.

PMID: 28991509 PMC: 5800363. DOI: 10.1080/19420862.2017.1389364.

References

Walker F, Burgess A . Internalisation and recycling of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on a murine myelomonocytic leukemia. J Cell Physiol. 1987; 130(2):255-61. DOI: 10.1002/jcp.1041300211. View

Yang W, Green K, Briones A, Burton D, Barbas 3rd C . CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol. 1995; 254(3):392-403. DOI: 10.1006/jmbi.1995.0626. View

Cook A, Braine E, Campbell I, Rich M, Hamilton J . Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001; 3(5):293-8. PMC: 64841. DOI: 10.1186/ar318. View

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577-9. PMC: 2936830. DOI: 10.1111/j.1476-5381.2010.00872.x. View

Mizushima S, Nagata S . pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 1990; 18(17):5322. PMC: 332193. DOI: 10.1093/nar/18.17.5322. View

Sabroe I, Hartnell A, Jopling L, Bel S, Ponath P, Pease J . Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol. 1999; 162(5):2946-55. View

Plater-Zyberk C, Joosten L, Helsen M, Hepp J, Baeuerle P, van den Berg W . GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis. 2006; 66(4):452-7. PMC: 1856054. DOI: 10.1136/ard.2006.057182. View

Farahat M, Yanni G, Poston R, Panayi G . Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 1993; 52(12):870-5. PMC: 1005218. DOI: 10.1136/ard.52.12.870. View

Thom G, Cockroft A, Buchanan A, Candotti C, Cohen E, Lowne D . Probing a protein-protein interaction by in vitro evolution. Proc Natl Acad Sci U S A. 2006; 103(20):7619-24. PMC: 1458619. DOI: 10.1073/pnas.0602341103. View

10.

Nicola N, Peterson L, Hilton D, Metcalf D . Cellular processing of murine colony-stimulating factor (Multi-CSF, GM-CSF, G-CSF) receptors by normal hemopoietic cells and cell lines. Growth Factors. 1988; 1(1):41-9. DOI: 10.3109/08977198809000245. View

11.

Baker K, Edwards B, Main S, Choi G, Wager R, Halpern W . Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003; 48(11):3253-65. DOI: 10.1002/art.11299. View

12.

Singh J, Christensen R, Wells G, Suarez-Almazor M, Buchbinder R, Lopez-Olivo M . Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009; (4):CD007848. PMC: 10636593. DOI: 10.1002/14651858.CD007848.pub2. View

13.

Wiley H, Herbst J, Walsh B, Lauffenburger D, Rosenfeld M, Gill G . The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem. 1991; 266(17):11083-94. View

14.

Schier R, McCall A, Adams G, Marshall K, Merritt H, Yim M . Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996; 263(4):551-67. DOI: 10.1006/jmbi.1996.0598. View

15.

Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom H . An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene. 1997; 187(1):9-18. DOI: 10.1016/s0378-1119(96)00628-2. View

16.

Symmons D . Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol. 2002; 16(5):707-22. DOI: 10.1053/berh.2002.0257. View

17.

Bell A, Magill M, McKane W, Kirk F, Irvine A . Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int. 1995; 14(5):177-82. DOI: 10.1007/BF00262295. View

18.

Pedersen M, Jacobsen H, Koefoed K, Hey A, Pyke C, Haurum J . Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010; 70(2):588-97. DOI: 10.1158/0008-5472.CAN-09-1417. View

19.

Burmester G, Feist E, Sleeman M, Wang B, White B, Magrini F . Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis. 2011; 70(9):1542-9. PMC: 3147227. DOI: 10.1136/ard.2010.146225. View

20.

Taylor P, Feldmann M . Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009; 5(10):578-82. DOI: 10.1038/nrrheum.2009.181. View